Eric D. Shaff - Jun 24, 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Jun 24, 2021
Transactions value $
$88,613
Form type
4
Date filed
6/28/2021, 07:15 AM
Next filing
Feb 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $88.6K +8.89K $9.97* 8.89K Jun 24, 2021 Common Stock 8.89K $9.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022.